Literature DB >> 21904581

Customizing systemic therapy in patients with advanced non-small cell lung cancer.

A M Sadowska1, V Nowé, A Janssens, E Boeykens, W A De Backer, P R Germonpré.   

Abstract

Lung cancer is the leading cause of cancer deaths worldwide. Standard chemotherapy has been shown to improve quality of life and has a modest influence on overall survival. This modest improvement in survival is partly due to the choice of chemotherapy regimens that have been based on prognostic factors such as age, performance status and comorbidities of the patient. This underlines the importance of developing a more personalized therapy for patients with non-small cell lung cancer. Such an approach may reduce the variation in how individual patients respond to medications by tailoring therapies to their genetic profile. In this review we focus on several aspects of customized therapy, looking not only at patient characteristics but also to tumor histology and specific tumor biomarkers.

Entities:  

Keywords:  bevacizumab; histology; non-small cell lung cancer; pemetrexed; personalized therapy; tyrosine kinase inhibitors

Year:  2011        PMID： 21904581      PMCID： PMC3150067          DOI： 10.1177/1758834011409000

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  58 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.

Authors:  Valentina Monica; Giorgio V Scagliotti; Paolo Ceppi; Luisella Righi; Alberto Cambieri; Marco Lo Iacono; Silvia Saviozzi; Marco Volante; Silvia Novello; Mauro Papotti
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

4.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.

Authors:  Paolo Ceppi; Marco Volante; Silvia Saviozzi; Ida Rapa; Silvia Novello; Alberto Cambieri; Marco Lo Iacono; Susanna Cappia; Mauro Papotti; Giorgio V Scagliotti
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

5.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.

Authors:  Christopher G Willett; Dan G Duda; Emmanuelle di Tomaso; Yves Boucher; Brian G Czito; Zeljko Vujaskovic; Gordana Vlahovic; Johanna Bendell; Kenneth S Cohen; Herbert I Hurwitz; Rex Bentley; Gregory Y Lauwers; Martin Poleski; Terence Z Wong; Erik Paulson; Kirk A Ludwig; Rakesh K Jain
Journal:  Nat Clin Pract Oncol       Date:  2007-05

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

9.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.

Authors:  V Rusch; D Klimstra; E Venkatraman; P W Pisters; J Langenfeld; E Dmitrovsky
Journal:  Clin Cancer Res       Date:  1997-04       Impact factor: 12.531

10.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205
View more
  5 in total

Review 1.  Epigenetics and the transition from acute to chronic pain.

Authors:  Thomas Buchheit; Thomas Van de Ven; Andrew Shaw
Journal:  Pain Med       Date:  2012-09-14       Impact factor: 3.750

2.  Detecting EGFR Mutations in Patients with Non-small Cell Lung Cancer.

Authors:  Z A Hammoudeh; O Antonova; R Staneva; D Nikolova; Y Kyuchukov; A Penev; T Mintchev; V Koleva; S Hadjidekova; D Toncheva
Journal:  Balkan J Med Genet       Date:  2018-10-29       Impact factor: 0.519

3.  In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non-small-cell lung cancer.

Authors:  Tse-Hung Huang; Alexander T H Wu; Tai-Shan Cheng; Kuan-Ting Lin; Chia-Jou Lai; Hao-Wen Hsieh; Peter Mu-Hsin Chang; Cheng-Wen Wu; Chi-Ying F Huang; Kuan-Yu Chen
Journal:  J Cell Mol Med       Date:  2019-10-22       Impact factor: 5.310

4.  Paeonol Suppresses Proliferation and Motility of Non-Small-Cell Lung Cancer Cells by Disrupting STAT3/NF-κB Signaling.

Authors:  Lei Zhang; Wen-Xu Chen; Ling-Li Li; Yu-Zhu Cao; Ya-Di Geng; Xiao-Jun Feng; Ai-Yun Wang; Zhao-Lin Chen; Yin Lu; Ai-Zong Shen
Journal:  Front Pharmacol       Date:  2020-11-12       Impact factor: 5.810

5.  Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations.

Authors:  Minakshi Guha; Elena Castellanos-Rizaldos; Pingfang Liu; Harvey Mamon; G Mike Makrigiorgos
Journal:  Nucleic Acids Res       Date:  2012-12-20       Impact factor: 16.971
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.